Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia-Reference-Cited by-同舟云学术

Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

Published:2012-04 Issue:4 Volume:36 Page:394-396
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Trifilio Steven M.,Rademaker Alfred W.,Newman Diane,Coyle Katherine,Carlson-Leuer Katrin,Mehta Jayesh,Altman Jessica,Frankfurt Olga,Tallman Martin S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference13 articles.

1. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia – an active and well-tolerated regimen;Ho;J Clin Oncol,1988

2. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia;Lazzarino;Eur J Haematol,1989

3. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia;Paciucci;Am J Clin Oncol,1990

4. Combination of mitoxantrone and etoposide in the treatment of myelodysplastic syndromes transformed into acute myeloid leukemia;Knauf;Leuk Lymphoma,1994

5. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide;Bow;J Clin Oncol,1996

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-omics data integration and drug screening of AML cancer using Generative Adversarial Network;Methods;2024-06

2. Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials;European Journal of Medical Research;2023-12-05

3. Decitabine combined with low-dose cytarabine, aclarubicin and rhG-CSF regimen may be a potential alternative for relapsed/refractory acute myeloid leukemia: A single-center study;memo - Magazine of European Medical Oncology;2023-11-20

4. Haploidentical Natural Killer Cell Therapy as an Adjunct to Stem Cell Transplantation for Treatment of Refractory Acute Myeloid Leukemia;Cell Transplantation;2023-01

5. A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML);Therapeutic Advances in Hematology;2022-01